Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
238
-
Total 13F shares, excl. options
-
74M
-
Shares change
-
+3.11M
-
Total reported value, excl. options
-
$4.11B
-
Value change
-
+$155M
-
Put/Call ratio
-
0.39
-
Number of buys
-
126
-
Number of sells
-
-95
-
Price
-
$55.49
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2016
299 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2016.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 238 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74M shares
of 132M outstanding shares and own 56.27% of the company stock.
Largest 10 shareholders include FMR LLC (12.8M shares), WELLINGTON MANAGEMENT GROUP LLP (12M shares), VANGUARD GROUP INC (5.39M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4M shares), BAILLIE GIFFORD & CO (3.39M shares), DODGE & COX (2.52M shares), STATE STREET CORP (2.2M shares), BlackRock Institutional Trust Company, N.A. (1.93M shares), BlackRock Fund Advisors (1.87M shares), and UBS ASSET MANAGEMENT AMERICAS INC (1.66M shares).
This table shows the top 238 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.